PRESTIGE-AF

PREVENTION OF STROKE IN INTRACEREBRAL HAEMORRHAGE SURVIVORS WITH ATRIAL FIBRILLATION

Pharmacology Substudy

Patient Information Sheet

WE INVITE YOU TO TAKE PART IN A RESEARCH STUDY

We are conducting a research study on the best stroke prevention for patients with atrial fibrillation (AF) who have recently had a bleeding in their brain, also called an "intracerebral haemorrhage" (ICH).

Within the PRESTIGE-AF trial you have been randomised to take a direct oral anticoagulant (DOAC). In this substudy, we will assess whether you take your DOAC regularly and whether the amount of medication within your blood, is at the level we would expect it to be.

- Before you decide whether to take part, it is important for you to understand why the research is being done and what it will involve.
- Please take time to read the following information carefully. Discuss it with friends and relatives if you wish.
- You are free to decide whether to take part in this trial. If you choose not to take part, this will not affect the care you get from your doctors. It will not impact your participation in PRESTIGE-AF if you decide not to take part in the substudy and you can withdraw at any time without any consequences for you.
- Ask us if there is anything that is not clear or if you would like more information.

BACKGROUND

In general, the requirement for a successful medication treatment is that the medicine is taken as prescribed and that the appropriate amount of medication actually reaches the patient.

However, it is sometimes difficult to adhere to a medication treatment plan. Moreover, other factors can influence the amount of medication that is absorbed into your body, including other medicines that you are taking, and other conditions that you may have. These complications can change your exposure to the medication and affect both the safety of the treatment and how effective it is.

We aim to find out if these issues are relevant to patients like you who are taking a DOAC. We equally plan to evaluate if patients succeed in regularly taking their DOAC and if their individual medication exposure is what we would expect it to be.

WHAT IS INVOLVED?

As you are a participant in the PRESTIGE-AF trial and you are one of the 327 patients receiving a DOAC, we are asking for you to decide whether you are willing to also take part in this substudy. DOAC medication exposure can be calculated by analysing the drug level in your blood at different time points before and after you take your DOAC within a dosing interval. In order to collect blood easily, we will use the dried blood spot technique (DBS). This technique is advantageous, because it only needs less than 4 drops of blood for an accurate analysis. DBS are sampled by dripping blood on a special card. These cards will then be posted to the study laboratory for analysis.

There are two possible ways in which you can participate in this substudy. If you decide on part 1, your blood will be collected during your scheduled visits at the study centre. A blood spot will be taken from the needle when your safety blood samples are collected. No additional blood draw is required, because those blood samples are already taken for the main trial.

In order to calculate your individual DOAC exposure, you can choose to take part in a more detailed version of this study (part 2). You (or your caregiver) will be asked to collect additional blood drops on a DBS paper after each scheduled visit, i.e. at home. These will be taken from the tiny blood vessels (capillaries) in your finger tip. A trained healthcare practitioner will teach you (or your caregiver) how to perform and document this capillary blood sampling on your own (see Figure 1). A short video will be shown to you, and you will be shown how to access this to watch it again at home if you wish (www.prestige-af.com). The first of four blood samples will be collected at the centre under supervision of your practitioner. Afterwards, you will collect three additional blood spots at home. The second spot should be generated the following morning, directly before you take your next DOAC. A third spot should be taken two hours after your DOAC intake and a fourth one eight hours after (see Figure 2). Please, remember to note the sampling times on the attached sheet. On the backside of that sheet you will be asked to answer a few questions concerning other drugs you might be taking as well as possible handling difficulties and to monitor your adherence on a visual scale. Please make sure that your patient ID is written down in the appropriate fields on both the card and the sheet. Let DBS dry for at least one hour after the last spot has been collected. Then, put DBS and scale into the designated, post-paid envelope and put it into a normal post box to send to the laboratory for analysis.

You can decide to participate in part 1 or part 2 of the substudy. In both parts the procedure described above will be repeated. This means that a new DBS will be created on each scheduled visit.



Figure 1 Capillary blood sampling to create and mail a DBS



Figure 2 Time course of capillary blood sampling

POTENTIAL BENEFIT OF THIS SUBSTUDY

Participating in this substudy, does not provide direct benefit for you. However, your data will help to reveal potential pitfalls of a DOAC treatment. We will be able to see whether patients in general succeed in taking a DOAC and whether DOAC medication levels in the blood are as expected. The laboratory results will be used for scientific analysis and will not be transmitted to you, because the medication levels in your blood only have meaning in comparison with other patients' data and these are confidential and only available at the end of the study.

POTENTIAL RISK OF THIS SUBSTUDY

As opposed to normal blood samples, the risks of sampling DBS are considered minimal. In the first part of this substudy, blood will be drawn as part of the blood sampling scheduled for safety during the main PRESTIGE-AF trial. In the second part, repetitive capillary blood sampling will be performed by you or your caregiver at home. In theory, local infections at the puncture site are possible but because single-use lancets (instrument used to pin prick finger) will be used and disinfectant swabs will be provided, the risk should be small. To minimise any risk, you will be trained in performing the procedure at each visit. The puncture site may slightly hurt, but the pain will ease after a few hours.

PARTICIPANT TIMELINE

The timeline is the same as for the timeline of the main trial. The substudy procedures will take place at your normal follow-up visits at 1, 6, 12, 24, and 36 months. If you participate in part 2 of the substudy, blood sampling for DBS will also include the day following your visits.

COMPENSATION

You will not receive any financial compensation for taking part in this substudy. You will be reimbursed for travel expenses to the hospital for the trial follow-up visits.

ABOUT THIS RESEARCH

This study is a substudy to a larger trial (PRESTIGE-AF)

FUNDER

A group of international researchers formed the PRESTIGE-AF consortium, which applied for research funding. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 754517.

SPONSOR

This trial is being sponsored by Imperial College London, they are responsible for the management and conduct of the trial.

COMPLAINTS AND LEGAL RIGHTS

Imperial College London holds insurance policies, which apply to this study. If you experience serious and enduring harm or injury as a result of taking part in this study, you may be eligible to claim compensation without having to prove that ICL is at fault. This does not affect your legal rights to seek compensation. If you are harmed due to someone's negligence, then you may have grounds for a legal action. Regardless of this, if you wish to complain, or have any concerns about any aspect of the way you have been treated during this study then you should immediately inform the Principle Investigator.

The National Health Service complaints mechanisms are also available to you. Patient Advice and Liaison Service (PALS) is an independent service available to patients and relatives who can listen to your concerns and help sort out any problems on your behalf.

CONFIDENTIALITY

Imperial College London is the sponsor for this study based in the United Kingdom. We will be using information from you and your

medical records in order to undertake this study and will act as the data controller for this study. This means that we are responsible for looking after your information and using it properly. Imperial College London will keep identifiable information about you for 10 years after the study has finished.

Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will keep the information about you that we have already obtained. To safeguard your rights, we will use the minimum personally-identifiable information possible.

You can find out more about how we use your information by contacting us at hello@prestige-af.org

Your Local NHS Trust will collect information from you and your medical records for this research study in accordance with our instructions.

Your Local NHS Trust will keep your name, NHS number and contact details confidential and will not pass this information to Imperial College London. Your Local NHS Trust will use this information as needed, to contact you about the research study, and make sure that relevant information about the study is recorded for your care, and to oversee the quality of the study. Certain individuals from Imperial College London and its delegates, as well as regulatory organisations may look at your medical and research records to check the accuracy of the research study. Imperial College London will only receive information without any identifying information. The people who analyse the information will not be able to identify you and will not be able to find out your name, NHS number or contact details.

Your Local NHS Trust will keep identifiable information about you from this study for 10 years after the study has finished.

DATA SHARING

When you agree to take part in a research study, the information about your health and care may be provided to researchers running other research studies in this organisation and in other organisations. These organisations may be universities, NHS organisations or companies involved in health and care research in this country or abroad. Your information will only be used by organisations and researchers to conduct research in accordance with the UK Policy Framework for Health and Social Care Research.

This information will not identify you and will not be combined with other information in a way that could identify you. The information will only be used for the purpose of health and care research, and cannot be used to contact you or to affect your care. It will not be used to make decisions about future services available to you, such as insurance.

This study is being sponsored and is being run by Imperial College London. However, there are 12 other European organisations in the PRESTIGE-AF Consortium with whom we will be sharing the anonymised results of this trial. These organisations are other Universities and Hospitals with specialist knowledge in different areas who will assist in the running of the trial and the analysis and publishing of the data.

The aim of this research is to improve patient care and to help us do that we ask for you to consent to your data being used in future research studies. These studies would need to go through the same rigorous ethical screening procedure that we did, to get access to your data. All shared data will be pseudonymised, and no identifiable information will be given to anyone outside of the direct care team who look after you.

FURTHER INFORMATION

It is important that you have enough information to decide whether to take part. If you have any questions, please contact hello@prestige-af.org

THANK YOU FOR TAKING THE TIME TO READ THIS INFORMATION.